Signals, Powered By EquityPandit
About Akums Drugs & Pharmaceuticals IPO
The Akums Drugs and Pharmaceuticals IPO amounts to Rs 1856.74 crores which is a book-built issue. The Offer consists of a fresh issue of one crore shares totaling Rs 680.00 crores. The second part consists of an offer for the sale of 1.73 crore shares worth Rs 1,176.74 crores.
Subscription for Akums Drugs and Pharmaceuticals IPO commences on July 30, 2024. The offer concludes on August 1, 2024. Allotment for Akums Drugs and Pharmaceuticals IPO is tentatively scheduled for August 2, 2024, Friday. The IPO will be listed on the Bombay Stock Exchange (BSE) and the National Stock Exchange (NSE). A tentative listing date on the stock exchanges is set for August 6, 2024, Tuesday.
The Akums Drugs and Pharmaceuticals IPO is priced between Rs 646 and Rs 679 per share. Retail investors are required to invest a minimum of Rs 14,938.
ICICI Securities Limited Axis Bank Limited Citigroup Global Markets India Private Limited and Ambit Private Limited are book-running lead managers of Akums Drugs and Pharmaceuticals IPO. Further, Link Intime India Private Ltd is the registrar for the issue.
Akums Drugs and Pharmaceuticals Company Details
Akums Drugs and Pharmaceuticals commenced its business since year 2004. Akums Drugs and Pharmaceuticals Limited is a pharmaceutical contract development and manufacturing organisation (CDMO). It offers a wide range of pharmaceutical products. The company offers services in India and abroad as well.
Akums has obtained national and international accreditations. Standardised procedures are also in place. This establishes trust in Effectiveness, Safety, and Quality.
The organisation holds certifications in the World Health Organization-Good Manufacturing Practice (WHO-GMP). It also has ISO 9001:2015 International Organization for Standardization (ISO) 14001:2015 ISO 50001:2018, ISO 45001:2018, and ISO 22000:2018.
Along with several international accreditations such as Food and Drug Administration (FDA) Philippines. National Medicine and Poisons Board (NMPB) Sudan National Drug Authority (NDA) Uganda as well as Cambodia Indonesia, Nigeria, and Malawi among others.
With a focus on the domestic market has witnessed a remarkable surge in its market share during FY24. The company’s value-based market share in the Indian domestic CDMO market surged from 9.30% in FY23 to an impressive 10.00% in FY24.
Its volume share in the total IPM market remained steady at 8.70%. In the Indian domestic CDMO market, Akums experienced a significant increase in value-based market share to a substantial 30.20% in FY24. This is up from 26.70% in FY21.
Akums Drugs and Pharmaceuticals IPO Details :
| IPO Date | July 30, 2024 to August 1, 2024 |
| Face Value | Rs 2 per share |
| Price Band | Rs 646 to Rs 679 per share |
| Lot Size | 22 Shares |
| Total Issue Size | 27,345,162 shares (aggregating up to Rs 1,856.74 Crores) |
| Fresh Issue | 10,014,727 shares (aggregating up to Rs 680.00 Crores) |
| Offer for Sale | 17,330,435 shares of Rs 2 (aggregating up to Rs 1,176.74 Crores) |
| Employee Discount | Rs 64 per share |
| Issue Type | Book Built Issue IPO |
| Listing At | BSE, NSE |
| Shareholding pre-issue | 14,73,56,280 |
| Shareholding post issue | 15,73,71,007 |
Akums Drugs and Pharmaceuticals IPO Schedule:
| IPO Open Date | Tuesday, July 30, 2024 |
| IPO Close Date | Thursday, August 1, 2024 |
| Basis of Allotment | Friday, August 2, 2024 |
| Initiation of Refunds | Monday, August 5, 2024 |
| The credit of Shares to Demate | Monday, August 5, 2024 |
| Listing Date | Tuesday, August 6, 2024 |
| Cut-off time for UPI mandate confirmation | 5 PM on August 1, 2024 |
Investors’ category and Akums Drugs IPO shares offered
| Investor Category | Shares Offered |
| QIB Shares Offered | Not less than 75.00% of the Net offer |
| Retail Shares Offered | Not more than 10.00% of the Offer |
| NII (HNI) Shares Offered | Not less than 15.00% of the Offer |
Akums Drugs and Pharmaceuticals IPO lot size, Applications, Shares and their value
The minimum lot size of Akums Drugs and Pharmaceuticals for an application is 22 shares. The minimum investment for a small Non-Institutional Investor (sNII) is 308 shares, amounting to Rs 209,132; for a big Non-Institutional Investor (bNII), it is 1,474 shares, amounting to Rs 10,00,846.
| Application | Lots | Shares | Amount (in Rs) |
| Retail (Min) | 1 | 22 | 14,938 |
| Retail (Max) | 13 | 286 | 1,94,194 |
| S-HNI (Min) | 14 | 308 | 2,09,132 |
| S-HNI (Max) | 66 | 1,452 | 9,85,908 |
| B-HNI (Min) | 67 | 1,474 | 10,00,846 |
Akums Drugs and Pharmaceuticals IPO GMP Details
As of Jul 29th, 2024, 09:58 AM, the latest GMP for Akums Drugs and Pharmaceuticals IPO stands at Rs 180.
Considering the price band of 679.00, the IPO’s estimated listing price is Rs 859 (market capitalisation price + today’s GMP). The projected percentage gain/loss per share is 26.51%.
Akums Drugs and Pharmaceuticals IPO Retail Subject to Sauda is Rs 3000.
The amount is yet to be specified for Akums Drugs and Pharmaceuticals IPO Small HNI Subject to Sauda. The GMP ranges from Rs 0 to a high of Rs 180.
Financials for Akums Drugs and Pharmaceuticals IPO
| Period Ended | 31-Mar-24 | 31-Mar-23 | 31-Mar-22 |
| Assets (Rs in crores) | 3,516.37 | 3,266.53 | 3,069.05 |
| Revenue (Rs in crores) | 4,212.21 | 3,700.93 | 3,694.52 |
| Profit After Tax (Rs in crores) | 0.79 | 97.82 | -250.87 |
| Net Worth (Rs in crores) | 709.5 | 717.19 | 621.98 |
| Reserves and Surplus (Rs in crores) | 861.01 | 868.7 | 787.79 |
| Total Borrowing (Rs in crores) | 491.56 | 536.97 | 357.95 |
Akums Drugs IPO’s Key Performance Indicators and Their Values
| KPI | Values |
| Return on Equity (ROE) | 0.11% |
| Return on capital employed (ROCE) | 3.37% |
| Debt/Equity | 0.69 |
| Return on net worth (RoNW) | -0.57 |
| Market price / Book value (P/BV) | 13.69 |
| Profit after tax (PAT) Margin (%) | 0.02 |
Objectives of Akums Drugs & Pharmaceuticals IPO
The Company intends to use funds raised from the fresh issue of Rs 680 crores for several purposes:
1. Repaying or prepaying existing debts of the Company and its subsidiaries.
2. Meeting additional working capital needs of the Company.
3. Pursuing opportunities for inorganic growth through acquisitions.
4. Utilizing funds for general corporate purposes.
The Offer for Sale will not provide any funds to the Company. The funds obtained from the Offer for Sale will not be included in the Net Proceeds
Frequently Asked Questions (FAQs)
Which document can be referred to check the details of Akums Drugs & Pharmaceuticals IPO?
The documents that can be referred which are uploaded on SEBI’s website are as follows –
a) Akums Drugs & Pharmaceuticals IPO – Draft Red Herring Prospectus (DRHP)
b) Akums Drugs & Pharmaceuticals IPO – Red Herring Prospectus (RHP)
What is the opening date of Akums Drugs & Pharmaceuticals IPO?
The opening date for Akums Drugs & Pharmaceuticals IPO is July 30, 2024. It falls on a Tuesday
What is the closing date of Akums Drugs & Pharmaceuticals IPO?
The closing date for Akums Drugs & Pharmaceuticals IPO is August 1, 2024. It falls on a Thursday
Who are the Book Running lead managers of Akums Drugs & Pharmaceuticals IPO?
ICICI Securities Limited Axis Capital Limited, Citigroup Global Markets India Private Limited, and Ambit Private Limited
Who is the Registrar of the offer?
The Registrar to offer is Link Intime India Private Limited
What is the tentative schedule for IPO Listing on Stock exchanges?
The tentative schedule for Akums Drugs & Pharmaceuticals IPO Listing on Stock exchanges is August 6, 2024, Tuesday.
